Omics for Understanding the Gut‐Liver‐Microbiome Axis and Precision Medicine

Abstract

Human metabolic disease opens a new view to understanding the contribution of the intestinal microbiome to drug metabolism and drug-induced toxicity in gut-liver function. The gut microbiome, a key determinant of intestinal inflammation, also plays a direct role in chronic inflammation and liver disease. Gut bacterial communities directly metabolize certain drugs, reducing their bioavailability and influencing individual variation in drug response. In addition, some microbiome-produced compounds may affect drug pharmacokinetics and pharmacodynamics via altered expression of metabolizing enzymes and drug transporters or genes coding for drug target proteins, drug response phenotypes, and disease states. Molecular-based high-throughput technologies are providing novel insight about host-gut microbiome interactions, homeostasis, and xenobiotic effects associated with wide variation in efficacy or toxicity in humans. It is envisioned that future approaches to treating and preventing liver disease will benefit from in-depth studies of the liver-microbiome axis. Thus, the microbiome shares a fundamental role in human physiology with various organ systems, and its importance must be considered in the rapid evolution of precision medicine. A new emerging perspective of understanding the effect of the gut microbiome on human response to drugs would be indispensable for developing efficacious, safe, and cost-effective precision therapies.

A Renal Clinician's Guide to the Gut Microbiota

“…The ultimate aim of precision medicine is to integrate an individual's genome, environment, and lifestyle to determine the best approach for the prevention or treatment of disease. 136 Personalized formulations of prebiotic, probiotic, and synbiotic supplements that can be used to modulate the gut microbiome represent an intriguing personalized No known trials in the CKD population however may be a strategy to modulate gut microbiota.…”

Microbiome Big-Data Mining and Applications Using Single-Cell Technologies and Metagenomics Approaches Toward Precision Medicine

“…The dietary intake (Wu et al, 2011; Liu et al, 2018) and environmental exposure such as administration of antibiotics (Pérez-Cobas et al, 2012; Raymond et al, 2016) can largely influence human gut microbiota. The gut microbiota would then respond to these factors, producing signals adjusting human distal organs including liver (Khalsa et al, 2017), brain (Dinan and Cryan, 2017), and lung (Budden et al, 2017), as described in Figure 2 . Both of microbes’ own structural components and metabolites produced by them can serve as the signal molecules.…”

“…The gut microbiota was confirmed to adjust liver metabolism (Kim et al, 2007; Khalsa et al, 2017). BAs, for example, derived from cholesterol in the liver, can be modified by microbiota in the distal small intestine and colon (Schroeder and Bäckhed, 2016).…”

Drug–Drug Interactions and Diagnostics for Drug Users With HIV and HIV/HCV Coinfections: Introduction

“…Finally, Duffy discussed the role of the gut microbiome in chronic intestinal inflammation, liver disease, and drug metabolism. Gut bacterial communities directly metabolize certain drugs, reducing their bioavailability and influencing individual variation in drug responses.…”